CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The healthcare stock market is unique amongst other markets because its accompanying industry is dependent on companies putting consumer needs above all else. Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future. Premier Health Group (OTC: PHGRF) (CSE: PHGI), Daré Bioscience Inc (NASDAQ: DARE), Jaguar Health Inc (NASDAQ: JAGX), and Oragenics Inc (NYSE American: OGEN) are 4 healthcare companies heating things up on Monday.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced last week that the Company is working with Bio Conscious Technologies to bring their artificial intelligence technology to Premier Health's active patient network. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, ''since the beginning, remote patient monitoring has been an integral component of our telemedicine app. DiaBits will enable our diabetic patients to dramatically increase glucose control and improve their quality of life. We are eager to work with the team at BCT to bring this innovative solution to our comprehensive telemedicine app.''
For More Information On Premier Health Group, Click Here
Daré Bioscience Inc (DARE), a leader in women's health innovation, saw its shares enjoy a boost of 131.11% in the market on Monday, with shares trading at $2.09 per share early in the afternoon. The Company today announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology.
Per the details of the announcement, the Company's study demonstrated that tamoxifen was effective when delivered intra-vaginally for three months in postmenopausal women suffering from VVA. Daré is currently conducting activities in preparation for future clinical work with DARE-VVA1, its proprietary vaginal formulation of tamoxifen. If successful, DARE-VVA1 could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in hormone-receptor-positive breast cancer patients.
For More Information On Daré Bioscience Inc, Click Here
Jaguar Health Inc (JAGX), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced earlier this month the voting results from the Special Meeting of Stockholders of the Company that was held on February 28, 2019.
Per the results of the meeting, seven proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the SEC on January 18, 2019.
For More Information On Jaguar Health Inc, Click Here
Oragenics Inc (OGEN), a leader in the development of new antibiotics against infectious diseases and treatments for oral mucositis, last week announced the enrollment of the 60th patient in its Phase 2 double-blind, placebo-controlled clinical trial of AG013. AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis bacteria strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria.
Following the announcement, Alan Joslyn, Chief Executive Officer of Oragenics, said, ''we are encouraged and pleased to have made this important intermediate progress. The number of patients interested in participating in the clinical trial highlights the need for new treatment options for prevention of severe oral mucositis in this patient population. while we are confident in the measures we have taken to potentially expedite the pace of patient enrollment in future periods and we remain optimistic about such enrollment rates…''
For More Information on Oragenics Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com